Simple Summary Most breast cancers co-express estrogen receptor α (ERα) and
progesterone receptor (PgR). These cancers are sensitive to endocrine therapy and, in …

The response to endocrine therapy in breast cancer correlates with estrogen receptor (ER)
and progesterone receptor (PR) status. ER-positive/PR-negative breast cancers respond …

The estrogen receptor α (ER) and the progesterone receptor (PgR) are one of the most
important prognostic and predictive immunohistochemical markers in breast cancer. Breast …

Response to endocrine therapy in breast cancer correlates with estrogen receptor (ER) and
progesterone receptor (PR) status. It was originally hypothesized that the ability of PR to …

Background Patient prognosis and response to endocrine therapy in breast cancer correlate
with protein expression of both estrogen receptor (ER) and progesterone receptor (PR), with …

Purpose To describe the clinical features and outcomes of estrogen receptor negative (ER-)
and progesterone receptor positive (PgR+) breast cancer. Methods We retrospectively …

Purpose The biology of breast cancer with a low expression level (1–10%) of estrogen
receptor (ER) remains a matter of confusion. The recent American Society of …

Background While most estrogen receptor-positive (ER+) breast cancers express
progesterone receptor (PR), a small subset of tumors exhibits an ER+/PR-phenotype despite …

Background Oestrogen receptor (ER) status provides invaluable prognostic and therapeutic
information in breast cancer (BC). When clinical decision making is driven by ER status, the …

Summary Oestrogen receptor (ER)-negative (–) progesterone receptor (PgR)-positive (+) is
the least common combination of steroid receptor expression observed in breast cancer …